Solid Tumor Test + Comprehensive Oncology

Price

$799.00

USD

Would you like us to call you?

One of our agents will contact you

FDA-Approved Assay

Introduction

Cancer remains one of the most significant global health challenges, requiring precision medicine approaches to improve treatment outcomes. SomaticCheck+, based on next-generation sequencing (NGS), provides a comprehensive genomic profiling (CGP) solution to identify actionable mutations, enabling oncologists to tailor cancer treatments according to each patient’s unique tumor genetics. This FDA-approved (IVD) assay serves as a companion diagnostic (CDx) to guide the selection of targeted therapies and immunotherapies for patients with solid tumors, in alignment with regulatory-approved drug indications and professional oncology guidelines.

Test Overview

[field_autop key="D1_Texto_1"]

Key Assay Features

[field_autop key="D2_Texto_2"]

Clinical Significance

[field_autop key="D3_Texto_3"]

Verification Study Summary

[field_autop key="D4_Texto_4"]

Clinical Utility and Benefits for Oncologists

[field_autop key="D5_Texto_5"]

Conclusion

[field_autop key="D6_Texto_6"]

Why Choose SomaticCheck+ Comprehensive?

[field_autop key="D7_Texto_7"]

References

[field_autop key="D8_Texto_8"]

Solid Tumor Test + Comprehensive Oncology

An FDA-approved kit solution from the U.S. for comprehensive genomic profiling. The test analyzes both DNA and RNA from FFPE tissue.

FDA-Approved Assay